share_log

Unveiling 7 Analyst Insights On Avidity Biosciences

Unveiling 7 Analyst Insights On Avidity Biosciences

揭示關於avidity biosciences的7個分析師見解
Benzinga ·  09/16 15:00
Across the recent three months, 7 analysts have shared their insights on Avidity Biosciences (NASDAQ:RNA), expressing a variety of opinions spanning from bullish to bearish.
在最近的三個月裏,有7位分析師就Avidity Biosciences (納斯達克:RNA)發表了自己的見解,表達了從看好到看淡的不同觀點。
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
下表提供了他們最近的評級快照,展示了情緒在過去30天中的演變情況,並將其與之前的月份進行比較。
The 12-month price targets, analyzed by analysts, offer insights with an average target of $68.86, a high estimate of $96.00, and a low estimate of $53.00. Observing a 4.33% increase, the current average has risen from the previous average price target of $66.00.
The 12-month price targets, analyzed by analysts, offer insights with an average target of $68.86, a high estimate of $96.00, and a low estimate of $53.00. Observing a 4.33% increase, the current average has risen from the previous average price target of $66.00.
Exploring Analyst Ratings: An In-Depth Overview
分析師評級:深入了解
In examining recent analyst...
通過審視...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論